<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463957</url>
  </required_header>
  <id_info>
    <org_study_id>REC 06/Q0108/200</org_study_id>
    <nct_id>NCT00463957</nct_id>
  </id_info>
  <brief_title>The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil</brief_title>
  <official_title>The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sildenafil and similar drugs have been used for several years to treat erectile dysfunction.&#xD;
      It has been noticed that in some people, sildenafil causes a subtle increase in the length of&#xD;
      time that visual images that we see are retained by the retina. It is thought that this might&#xD;
      be due to an effect of sildenafil on inhibiting an enzyme called phosphodiesterase type 6&#xD;
      (PDE6) which is present in the retina. By giving single oral doses of sildenafil and a&#xD;
      similar drug called tadalafil which has less effect on PDE6, we hypothesise that this is the&#xD;
      mechanism of the change in vision caused by sildenafil. By performing computerised visual&#xD;
      test, we plan to compare the effects of sildenafil, tadalafil and placebo tablets on vision&#xD;
      in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual persistence</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>reaction time</measure>
  </primary_outcome>
  <enrollment>12</enrollment>
  <condition>Erectile Dysfunction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  18-55 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant medical or psychiatric illness&#xD;
&#xD;
          -  Cardiac disease&#xD;
&#xD;
          -  Hyper or hypotension&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Stroke&#xD;
&#xD;
          -  Sickle cell anaemia&#xD;
&#xD;
          -  Multiple myeloma&#xD;
&#xD;
          -  Leukaemia&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Peyronie's disease&#xD;
&#xD;
          -  Priapism&#xD;
&#xD;
          -  Subjects receiving prescribed medications&#xD;
&#xD;
          -  Subjects with known visual abnormalities other than refractive errors, including&#xD;
             retinitis pigmentosa, optic neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morris J Brown</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>January 11, 2010</last_update_submitted>
  <last_update_submitted_qc>January 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <keyword>sildenafil</keyword>
  <keyword>tadalafil</keyword>
  <keyword>phosphodiesterase</keyword>
  <keyword>visual persistence</keyword>
  <keyword>reaction time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

